Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
August 11 2020 - 5:48PM
Business Wire
Seres Therapeutics, Inc. (Nasdaq:MCRB) (“Seres”), a leading
microbiome therapeutics platform company developing a novel class
of multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease,
today announced that it is commencing an underwritten registered
public offering of 8,000,000 shares of its common stock. As part of
this offering, Seres intends to grant the underwriters a 30-day
option to purchase up to an additional 1,200,000 shares of its
common stock on the same terms and conditions. The proposed
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the size or terms of the proposed offering. All
of the shares in the proposed offering are to be sold by Seres.
Cowen and Company, LLC and Piper Sandler & Co. are acting as
joint book-running managers for the offering. Canaccord Genuity LLC
and Oppenheimer & Co. Inc. are acting as co-managers.
The common stock described are being offered by Seres pursuant
to a shelf registration statement on Form S-3, including a
prospectus, which was automatically effective upon filing on August
11, 2020. A preliminary prospectus supplement and a final
prospectus supplement to the prospectus describing the terms of the
offering will be filed with the SEC. The offering will be made only
by means of a written prospectus and prospectus supplement that
form a part of the effective registration statement. Copies of the
preliminary prospectus supplement and accompanying prospectus
relating to the offering may be obtained, when available, by
contacting: Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by
telephone at (833) 297-2926, or by email at
postsalemanualrequests@broadridge.com or Piper Sandler & Co.,
800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at
(800) 747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200811005851/en/
Carlo Tanzi, Ph.D. ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024